Medtronic begins pacemaker trials
This article was originally published in Clinica
Executive Summary
Medtronic has begun European trials of its new Kappa 400 pacemaker. Dual-chamber devices have been implanted in patients in Italy and Denmark. A single-chamber version will also be evaluated in the 50-patient trial. Medtronic spokesman Dick Reid says data from a separate trial of a similar but larger device will be used for seeking regulatory approvals, although the larger pacemaker will probably not be marketed.
You may also be interested in...
US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.
Demi Moore’s Wonderbelly Antacid Investment Lands Supporting Role In Her Promotional Posts
Wonderbelly Antacids “free from” ad claims work but failing to disclose Demi Moore is an investor in her promotions doesn’t, NAD says. Dakota Nutrition fails again on NAD’s test of its testing for elderberry in its supplements.